Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€23.80
Change (%)0.00 (0.00%)
Volume0
Data as of 09/22/17 4:07 a.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
12-Sep-2017ERYTECH to Present at Morgan Stanley Global Healthcare Conference
LYON, France--(BUSINESS WIRE)--Sep. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR: EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017... 
 Printer Friendly Version
11-Sep-2017ERYTECH Reports First Half 2017 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 12th at 02:30 pm CEST/08:30 am EDT Positive final results from Phase 2b study of eryaspase (GRASPA®) for the treatment of metastatic pancreatic cancer presented at the European Society for Medical Oncology (ESMO) 2017 Congress Meeting with the U.S. Food and Drug Administration (FDA) to seek guidance for further clinical development of eryaspase in panc... 
 Printer Friendly Version
08-Sep-2017ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
Full data demonstrates statistically significant improvement in both overall survival and progression-free survival for eryaspase as second-line treatment of metastatic pancreatic cancer Data to be presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid (September 8-12) Meeting with U.S. FDA upcoming to discuss the design of Phase 3 study Company to host Investor &... 
 Printer Friendly Version
06-Sep-2017ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
LYON, France--(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Second Quarter 2017 conference call and webcast on Tuesday, September 12, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights. The call ... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/13/17
Third Quarter 2017 Financial Results and Business Update: Press Release: Monday, November 13, 2017 (after market)
11/14/17 3:00 p.m. CET
Third Quarter 2017 Financial Results and Business Update: Conference Call
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top